29:
308:
350:
InChI=1S/C32H31F9N4O5/c1-3-22-14-26(24-13-19(30(33,34)35)7-8-25(24)45(22)29(48)49-4-2)44(28-42-15-23(16-43-28)50-9-5-6-27(46)47)17-18-10-20(31(36,37)38)12-21(11-18)32(39,40)41/h7-8,10-13,15-16,22,26H,3-6,9,14,17H2,1-2H3,(H,46,47)/t22-,26+/m1/s1
417:
Ballantyne, Christie M.; Ditmarsch, Marc; Kastelein, John JP; Nelson, Adam J.; Kling, Douglas; Hsieh, Andrew; Curcio, Danielle L.; Maki, Kevin C.; Davidson, Michael H.; Nicholls, Stephen J. (July 2023).
451:
Nicholls, Stephen J.; Ditmarsch, Marc; Kastelein, John J.; Rigby, Scott P.; Kling, Douglas; Curcio, Danielle L.; Alp, Nicholas John; Davidson, Michael H. (August 2022).
322:
520:
553:
342:
453:"Lipid lowering effects of the CETP inhibitor obicetrapib in combination with high-intensity statins: a randomized phase 2 trial"
509:
78:
54:
180:
492:
543:
548:
538:
229:
563:
420:"Obicetrapib plus ezetimibe as an adjunct to high-intensity statin therapy: A randomized phase 2 trial"
384:(by up to 30%) and non-high-density lipoprotein cholesterol (non-HDL-C) (by up to 44%), and increased
376:. In a clinical trial, as an add-on to statins, compared with placebo, it decreased concentrations of
558:
568:
95:
330:
CC1C(C2=C(N1C(=O)OCC)C=CC(=C2)C(F)(F)F)N(CC3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F)C4=NC=C(C=N4)OCCCC(=O)O
400:
as AMG-899 and was abandoned in 2017. In 2020, Amgen licensed the drug to NewAmsterdam Pharma.
474:
169:
464:
431:
381:
245:
104:
189:
369:
532:
452:
129:
373:
469:
436:
419:
284:
160:
478:
20:
140:
149:
28:
493:"NewAmsterdam Pharma concludes enrolment in LDL lowering therapy trial"
388:
concentration (by up to 165%). As of 2023, it is in a Phase III trial.
115:
220:
209:
397:
385:
377:
307:
298:
521:
NewAmsterdam bags $ 196M to resurrect Amgen's discarded CETP drug
200:
510:
Amgen kills off CETP inhibitor after seeing Merck data
296:
283:
244:
239:
219:
199:
179:
159:
139:
114:
94:
69:
53:
48:
40:
35:
128:
103:
86:4-methyl-amino]pyrimidin-5-yl]oxybutanoic acid
8:
19:
168:
27:
468:
435:
188:
409:
396:Obicetrapib was initially developed by
347:
327:
148:
83:
18:
228:
7:
208:
119:
14:
268:
262:
256:
355:Key:NRWORBQAOQVYBJ-GJZUVCINSA-N
424:Journal of Clinical Lipidology
274:
250:
1:
585:
470:10.1038/s41591-022-01936-7
437:10.1016/j.jacl.2023.05.098
372:that is intended to treat
240:Chemical and physical data
554:Trifluoromethyl compounds
338:
318:
74:
26:
497:Clinical Trials Arena
368:is an experimental
23:
544:Experimental drugs
363:
362:
309:Interactive image
16:Chemical compound
576:
549:Carboxylic acids
523:
518:
512:
507:
501:
500:
489:
483:
482:
472:
463:(8): 1672–1678.
448:
442:
441:
439:
414:
382:apolipoprotein B
380:(by up to 51%),
311:
291:
276:
270:
264:
258:
252:
232:
212:
192:
172:
152:
132:
122:
121:
107:
44:TA-8995; AMG-899
31:
24:
22:
584:
583:
579:
578:
577:
575:
574:
573:
539:CETP inhibitors
529:
528:
527:
526:
519:
515:
508:
504:
499:. 26 July 2023.
491:
490:
486:
457:Nature Medicine
450:
449:
445:
416:
415:
411:
406:
394:
359:
356:
351:
346:
345:
334:
331:
326:
325:
314:
289:
279:
273:
267:
261:
255:
235:
215:
195:
175:
155:
135:
118:
110:
90:
87:
82:
81:
65:
62:Investigational
17:
12:
11:
5:
582:
580:
572:
571:
566:
561:
556:
551:
546:
541:
531:
530:
525:
524:
513:
502:
484:
443:
430:(4): 491–503.
408:
407:
405:
402:
393:
390:
370:CETP inhibitor
361:
360:
358:
357:
354:
352:
349:
341:
340:
339:
336:
335:
333:
332:
329:
321:
320:
319:
316:
315:
313:
312:
304:
302:
294:
293:
287:
281:
280:
277:
271:
265:
259:
253:
248:
242:
241:
237:
236:
234:
233:
225:
223:
217:
216:
214:
213:
205:
203:
197:
196:
194:
193:
185:
183:
177:
176:
174:
173:
165:
163:
157:
156:
154:
153:
145:
143:
137:
136:
134:
133:
125:
123:
112:
111:
109:
108:
100:
98:
92:
91:
89:
88:
85:
77:
76:
75:
72:
71:
67:
66:
64:
63:
59:
57:
51:
50:
46:
45:
42:
38:
37:
33:
32:
15:
13:
10:
9:
6:
4:
3:
2:
581:
570:
567:
565:
562:
560:
557:
555:
552:
550:
547:
545:
542:
540:
537:
536:
534:
522:
517:
514:
511:
506:
503:
498:
494:
488:
485:
480:
476:
471:
466:
462:
458:
454:
447:
444:
438:
433:
429:
425:
421:
413:
410:
403:
401:
399:
391:
389:
387:
383:
379:
375:
371:
367:
353:
348:
344:
337:
328:
324:
317:
310:
306:
305:
303:
300:
295:
288:
286:
282:
249:
247:
243:
238:
231:
230:ChEMBL3785197
227:
226:
224:
222:
218:
211:
207:
206:
204:
202:
198:
191:
187:
186:
184:
182:
178:
171:
167:
166:
164:
162:
158:
151:
147:
146:
144:
142:
138:
131:
127:
126:
124:
117:
113:
106:
102:
101:
99:
97:
93:
84:
80:
73:
68:
61:
60:
58:
56:
52:
47:
43:
39:
36:Clinical data
34:
30:
25:
564:Ethyl esters
516:
505:
496:
487:
460:
456:
446:
427:
423:
412:
395:
374:dyslipidemia
365:
364:
55:Legal status
49:Legal status
559:Pyrimidines
366:Obicetrapib
292: g·mol
105:866399-87-3
70:Identifiers
41:Other names
21:Obicetrapib
569:Quinolines
533:Categories
404:References
297:3D model (
285:Molar mass
190:8O74K609HN
161:ChemSpider
96:CAS Number
79:IUPAC name
479:1546-170X
141:DrugBank
130:11498596
392:History
290:722.609
246:Formula
170:9673402
150:DB14890
116:PubChem
477:
323:SMILES
221:ChEMBL
210:D12900
398:Amgen
386:HDL-C
378:LDL-C
343:InChI
299:JSmol
475:ISSN
201:KEGG
181:UNII
465:doi
432:doi
120:CID
535::
495:.
473:.
461:28
459:.
455:.
428:17
426:.
422:.
260:31
254:32
481:.
467::
440:.
434::
301:)
278:5
275:O
272:4
269:N
266:9
263:F
257:H
251:C
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.
